Bladder Cancer Market

The increasing awareness about bladder diseases and available therapies is driving the market growth

Due to rising healthcare costs, expanding healthcare spending, and the mounting incidence of bladder cancer, the market for treatments and diagnostics for bladder cancer may experience substantial expansion. For instance, the World Bladder Cancer Patient Coalition has declared March 2022 to be "Don't Go Red" Month for Bladder Cancer knowledge in an effort to increase public knowledge of the disease's warning signs and symptoms. Early detection is essential for improving long-term survival and quality of life. Over the forecast period, such activities are anticipated to promote market growth.

The market is also expected to be driven by a number of strategies used by the major industry competitors, such as product launches and mergers and acquisitions. For instance, Merck, also known as MSD outside of the United States and Canada, reported a label update for KEYTRUDA, its anti-PD-1 medication, in August 2021 for first-line advanced urothelial carcinoma (bladder cancer) in the United States.

The 10th most frequent cancer in the world is bladder cancer. For instance, the American Cancer Society reports that around 83,730 people in the United States will receive a bladder cancer diagnosis in 2021. Additionally, $1.18 million in charitable donations and university investments were used to build bladder cancer research centres at the University of Birmingham in the UK. The ageing population, which is more susceptible to bladder cancer, is another factor driving market expansion throughout the predicted period. Due to weakened immune cells that fight against cancerous bladder tissue, the elderly are more susceptible to urinary tract cancer.

In January 2021, the American society of clinical oncology (ASCO) organisation reported that 90% of bladder cancer patients were over the age of 55.  The American Cancer Society reported in 2019 that smoking and job exposure can both contribute to the development of bladder cancer. Thus, driving the Bladder Cancer market revenue.

The Global Bladder Cancer Market Industry is projected to experience substantial growth in the coming years. By 2035, the market is expected to reach 9.95 USD Billion, indicating a robust demand for bladder cancer therapies and diagnostics. This growth trajectory is supported by various factors, including the rising incidence of bladder cancer, advancements in treatment modalities, and increased awareness among the public. The market's expansion reflects the ongoing efforts to improve patient outcomes and the commitment of stakeholders to address the challenges posed by bladder cancer.

The Global Bladder Cancer Market Industry is experiencing growth due to the increasing incidence of bladder cancer worldwide. According to health statistics, bladder cancer ranks as the fourth most common cancer in men and the ninth in women, leading to a substantial patient population requiring treatment. This rise in cases is attributed to various factors, including smoking, exposure to certain chemicals, and aging populations. As the global population ages, the number of diagnosed cases is projected to increase, thereby driving demand for innovative therapies and diagnostic tools within the Global Bladder Cancer Market Industry.

Innovations in treatment modalities are significantly influencing the Global Bladder Cancer Market Industry. The development of targeted therapies and immunotherapies has transformed the treatment landscape, offering patients more effective options with fewer side effects. For instance, the introduction of immune checkpoint inhibitors has shown promising results in advanced bladder cancer cases. These advancements not only improve patient outcomes but also contribute to the overall market growth, as healthcare providers increasingly adopt these novel therapies. The Global Bladder Cancer Market Industry is expected to reach 6.07 USD Billion in 2024, reflecting the impact of these advancements.

Investment in research and development is a critical driver for the Global Bladder Cancer Market Industry. Pharmaceutical companies and research institutions are increasingly allocating resources to discover new therapeutic agents and improve existing treatments. This focus on R&D is essential for addressing unmet medical needs and advancing the understanding of bladder cancer biology. As a result, the market is likely to see a surge in novel drug approvals and clinical trials, fostering innovation. The Global Bladder Cancer Market Industry is projected to grow at a CAGR of 4.59% from 2025 to 2035, reflecting the positive impact of these investments.

Increased awareness regarding bladder cancer symptoms and risk factors is propelling the Global Bladder Cancer Market Industry. Public health campaigns and educational initiatives are encouraging individuals to seek early diagnosis and treatment, which is crucial for improving survival rates. Screening programs, particularly in high-risk populations, are becoming more prevalent, leading to earlier detection of the disease. This proactive approach not only enhances patient outcomes but also stimulates market growth as more individuals are diagnosed and treated. The Global Bladder Cancer Market Industry is poised for expansion as awareness continues to rise.

Regulatory support plays a vital role in shaping the Global Bladder Cancer Market Industry. Agencies such as the FDA and EMA are streamlining approval processes for new therapies, which facilitates quicker access to innovative treatments for patients. This supportive regulatory environment encourages pharmaceutical companies to invest in bladder cancer research and development, knowing that their products can reach the market more efficiently. As a result, the Global Bladder Cancer Market Industry is likely to benefit from an influx of new therapies, enhancing treatment options for patients and contributing to overall market growth.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Bladder Cancer Market dominated this market in 2022 (45.80%). This is a result of the region's expanding R&D activities and well-established healthcare infrastructure. The existence of numerous biologics and biopharmaceutical firms is another factor that has contributed to the bladder cancer therapies and diagnostics market's size and stellar growth.

In the United States, there are approximately 81,180 new cases of bladder cancer in 2022 (61,700 in men and 19,480 in women), according to the American Cancer Society's January 2022 statistics. Therefore, the need for bladder cancer detection and treatment is anticipated to rise as its prevalence rises, supporting the market's expansion. Further, the U.S. Bladder Cancer market held the largest market share, and the Canada Bladder Cancer market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: BLADDER CANCER MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Bladder Cancer market accounted for the healthy market share in 2022. This is due to the significant increase in bladder cancer cases in the European region. Bladder cancer is ranked as the 11th most dangerous disease in the United Kingdom, with an estimated 10,300 cases reported in the country between 2016 and 2018. Further, the German Bladder Cancer market held the largest market share, and the U.K Bladder Cancer market was the fastest growing market in the European region

The Asia Pacific Bladder Cancer market is expected to register significant growth from 2023 to 2032. This growth is primarily attributable to improved bladder disease awareness and novel diagnostic and therapeutic approaches. Leading market players invest heavily in Asia because they think it is a lucrative market for bladder cancer and as a result, the market there is growing. Every year that goes by, the number of bladder cancer diagnoses rises significantly in the Asia Pacific region. In 2018, there were 10,231 fatalities and 18,921 cases of bladder cancer in India.

Moreover, China’s Bladder Cancer market held the largest market share and the Indian Bladder Cancer market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their Type lines, which will help the Bladder Cancer market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new Type launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Bladder Cancer industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Bladder Cancer industry to benefit clients and increase the market sector. In recent years, the Bladder Cancer industry has offered some of the most significant advantages to medicine. Major players in the Bladder Cancer market, including AstraZeneca Plc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Novartis International AG, Pfizer Inc., Sanofi S.A., Merck & Co.

Inc., Accord Healthcare, and Bedford Lab, are attempting to increase market demand by investing in research and development Types.

Pharmaceuticals of all kinds are discovered, developed, produced, and sold by Astellas Pharma Inc (Astellas). Marketed treatments for the treatment of a variety of urological disorders, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation are included in the company's product portfolio. Its pipeline includes drug candidates for the treatment of various diseases, including acute myeloid leukaemia (AML), urothelial cancer, gastric cancer, gastroesophageal junction cancer, anaemia linked to chronic kidney disease (CKD) in dialysis patients, rheumatoid arthritis, and non-dialysis patients.

With the help of a network of subsidiaries and affiliates, it conducts business in the Americas, Australia, Europe, Asia, and Oceania. Tokyo, Japan serves as the headquarters of Astellas. Preliminary results from Cohort H of the EV-103 study, which examines PADCEV (enfortumab vedotin-jeff) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based treatment, were released in February 2022 by Astellas Pharma Inc. and Seagen Inc.

A biopharmaceutical firm called Merck & Co Inc (Merck) is dedicated to the discovery, development, production, and marketing of prescription drugs, biologic therapies, vaccines, and animal health products. It provides products on prescription for the treatment of conditions like diabetes, cancer, immunological diseases, cardiovascular disease, and cancer. Keytruda (pembrolizumab), which is used to treat urothelial carcinoma, received U.S. Food and Drug Administration approval in August 2021, according to Merck, a leading global biopharmaceutical business.